About Esperion Therapeutics
Esperion Therapeutics (NASDAQ:ESPR) focuses on the research, development, and commercialization of innovative lipid management products to improve cardiovascular health. Its primary projects revolve around the development of therapies aimed at reducing bad cholesterol levels, with a notable emphasis on bempedoic acid and its combinations as a new option for patients struggling with cardiovascular diseases. Esperion aims to address the significant unmet medical needs in the cardiovascular space, aspiring to reduce the global burden of cardiovascular diseases through its groundbreaking therapies. The company's objectives are geared towards improving the accessibility and effectiveness of cholesterol management options for patients and healthcare providers, ultimately striving to lead the advancement in cardiovascular health solutions on a global scale.
Snapshot
Operations
Products and/or services of Esperion Therapeutics
- Nexletol (bempedoic acid) is a once-daily oral medication designed to lower LDL cholesterol.
- Nexlizet combines bempedoic acid with ezetimibe to offer an advanced cholesterol-lowering treatment option.
- Research on bempedoic acid's potential benefits in reducing cardiovascular events in high-risk patients.
- Development of LDL-C lowering therapies that focus on unique mechanisms to address statin intolerance.
- Collaboration on innovative projects aimed at discovering new treatments for cardiometabolic diseases.
- Expansion of their portfolio into next-generation therapies targeting genetic drivers of lipid disorders.
Esperion Therapeutics executive team
- Mr. Sheldon L. Koenig M.B.A.President, CEO & Director
- Mr. Benjamin Halladay M.B.A.Chief Financial Officer
- Mr. Benjamin O. Looker J.D.General Counsel & Corporate Secretary
- Mr. Glenn P. BrameChief Technical Operations Officer
- Tiffany Aldrich M.B.A.Associate Director of Corporate Communications
- Ms. Betty Jean SwartzChief Business Officer
- LeAnne Bloedon M.S.VP & Head of Development
- Mr. John B. Harlow Jr.Chief Commercial Officer
- Dr. Stephen PinkoskyVice President of Drug Discovery of Early Pre-Clinical Development